300246.SHE Guangdong Biolight Meditech Co Ltd
- Market cap
- CNY 3.18B
- P/E
- -
- P/B
- 2.94x
- ROE
- -7.0%
- Dividend yield
- 0.96%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300246.SHE undervalued?
Graham numberThe Graham number of Guangdong Biolight Meditech Co Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Guangdong Biolight Meditech Co Ltd fundamental analysis
No fundamental analysis for Guangdong Biolight Meditech Co Ltd yet.
Guangdong Biolight Meditech Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Guangdong Biolight Meditech Co Ltd
Guangdong Biolight Meditech Co., Ltd. engages in the research and development, production, sale, and service of medical devices products and solutions in China. It operates in two segments, Life Information and Support, and Kidney Disease. The company offers emergency and critical care monitor, subcritical care monitor, general ward monitor, outpatient monitor, neonatal monitor, infusion pump, electrocardiograph, maternal and fetal monitor, defibrillator, multifunctional sus…
Full company profileGuangdong Biolight Meditech Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Guangdong Biolight Meditech Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 594M | 711M | 813M | 826M | 1.40B | 1.09B | 1.18B | 1.19B | 1.06B | 1.10B | 1.09B |
| Gross Profit | 240M | 265M | 302M | 328M | 650M | 356M | 355M | 380M | 278M | 282M | 251M |
| Operating Income | 83.0M | 86.4M | 93.0M | 89.8M | 414M | 76.2M | 25.7M | -26.1M | -66.9M | -16.8M | -2.50M |
| EBITDA | 104M | 99.6M | 108M | 112M | 448M | 126M | 78.0M | 19.4M | 14.9M | 27.3M | -26.2M |
| Net Income | 67.1M | 57.5M | 64.2M | 64.7M | 346M | 63.8M | 22.1M | -65.2M | -71.4M | -69.4M | -75.4M |
| EPS | 0.31 | 0.26 | 0.29 | 0.30 | 1.58 | 0.29 | 0.08 | -0.25 | -0.27 | -0.26 | -0.28 |
| Balance Sheet | |||||||||||
| Total Assets | 687M | 800M | 918M | 961M | 1.61B | 1.72B | 2.44B | 2.53B | 2.50B | 2.52B | 2.34B |
| Total Liabilities | 182M | 246M | 296M | 376M | 574M | 727M | 936M | 1.15B | 1.21B | 1.31B | 1.19B |
| Shareholders' Equity | 464M | 506M | 562M | 548M | 918M | 894M | 1.42B | 1.31B | 1.22B | 1.14B | 1.08B |
| Cash & Short-term Investments | 183M | 160M | 170M | 186M | 483M | 337M | 437M | 499M | 730M | 677M | 363M |
| Total Debt | 3.50M | 33.8M | 92.6M | 154M | 241M | 355M | 428M | 585M | 598M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 50.8M | 72.3M | 81.2M | 81.4M | 456M | 80.6M | 141M | 129M | -8.64M | 90.4M | - |
| Capital Expenditure | 44.0M | 44.7M | 99.8M | 47.0M | 68.4M | 163M | 212M | 220M | 104M | 167M | 114M |
| Free Cash Flow | 6.80M | 27.6M | -18.6M | 34.4M | 387M | -82.8M | -71.1M | -91.3M | -112M | -77.0M | -15.1M |
| Ratios | |||||||||||
| ROE | 14.5% | 11.4% | 11.4% | 11.8% | 37.7% | 7.1% | 1.6% | -5.0% | -5.9% | -6.1% | -7.0% |
| ROA | 9.8% | 7.2% | 7.0% | 6.7% | 21.5% | 3.7% | 0.9% | -2.6% | -2.9% | -2.8% | -3.2% |
| Net Profit Margin | 11.3% | 8.1% | 7.9% | 7.8% | 24.8% | 5.8% | 1.9% | -5.5% | -6.7% | -6.3% | -6.9% |
| Debt to Equity | 0.01x | 0.07x | 0.16x | 0.28x | 0.26x | 0.40x | 0.30x | 0.45x | 0.49x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Guangdong Biolight Meditech Co Ltd dividends
- Dividend yield
- 0.96%
- Forward dividend
- 0.05 CNY
- Payout ratio
- -
- Ex-dividend date
- Nov 26, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 30.6M | 0.12 | - |
| 2024 | CNY 17.6M | 0.07 | - |
| 2023 | CNY 46.3M | 0.18 | - |
| 2022 | CNY 35.1M | 0.13 | 158.8% |
| 2021 | CNY 58.4M | 0.27 | 91.6% |
| 2020 | CNY 29.2M | 0.13 | 8.4% |
| 2019 | CNY 14.6M | 0.07 | 22.6% |
| 2018 | CNY 9.86M | 0.05 | 15.4% |
| 2017 | CNY 8.08M | 0.04 | 14.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.5:1 on May 25, 2023.
Who owns Guangdong Biolight Meditech Co Ltd
- Insiders 32.81%
- Institutions 1.96%
- Public & others 65.23%
- Shares outstanding 265M
- Free float 184M
Guangdong Biolight Meditech Co Ltd company profile
- Company name
- Guangdong Biolight Meditech Co Ltd
- Ticker
- 300246.SHE
- ISIN
- CNE1000015Q4
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Jul 19, 2011
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 1,335
- Fiscal year end
- December
- Address
- Biolight Technology Park, Zhuhai, China, 519085
- Phone
- 86 75 6339 9999
- Website
- blt.com.cn
About Guangdong Biolight Meditech Co Ltd
Guangdong Biolight Meditech Co., Ltd. engages in the research and development, production, sale, and service of medical devices products and solutions in China. It operates in two segments, Life Information and Support, and Kidney Disease. The company offers emergency and critical care monitor, subcritical care monitor, general ward monitor, outpatient monitor, neonatal monitor, infusion pump, electrocardiograph, maternal and fetal monitor, defibrillator, multifunctional suspension device, internet of things, and central station; hemodiafiltration equipment, peritoneal dialysis equipment, liquid supply system, and hemodialysis water equipment; and finger clip oximeter, sphygmomanometer, fetal heart rate monitor, body temperature monitoring system, and home medical mall, as well as hemoperfusion devices, high throughput and low flu hemodialyzer, hemodialysis concentrate, dry powder, citric acid disinfectant, tube/puncture needle, dialysate filter, and dialysis fluid filter. It offers its products under JUNKANG MEDICAL, BIOLIGHT HEALTHCARE, TRUSTRONG, BR Medical Service, SHENBA, HUA VUE MEDICAL, BOAO TIANSHENG, and other brand names. The company serves medical institutions through direct sales channel. It also exports its products. The company was founded in 1993 and is headquartered in Zhuhai, China.
Guangdong Biolight Meditech Co Ltd management
5- Mr. Jinyuan YanChairman & President · born 1963
- Ms. Wei XuFinancial Director & Director · born 1975
- Mr. Yongxing YangSecretary of the Board of Directors · born 1974
- Shuyin HuAccounting Supervisor
- Mr. Daoguo ZhangVP & Non-Independent Director · born 1980